Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.
Key PointsViking Therapeutics has significant upside potential based on Wall Street targets.
The consensus price target for Viking Therapeutics (NASDAQ: VKTX) stands at around $92, suggesting a potential 162% increase from its current stock price. While this presents an appealing investment opportunity, skeptics question whether it is justified. The stock's success hinges on its lead drug, VK2735, a dual GLP-1 and GIP agonist being developed for obesity and type 2 diabetes.
VK2735 boasts two potential advantages over competitors: a steeper rate of weight loss and a unique dual-formulation therapy (oral and subcutaneous). The dual formulation could allow patients to achieve substantial weight loss through a subcutaneous dose, followed by a more convenient oral maintenance treatment. These attributes could help VK2735 capture market share in a highly competitive landscape.
Investors are eagerly awaiting the results of its Phase 3 trials for VK2735's subcutaneous formulation, expected in the second half of 2027, and the oral formulation slated to begin later this year, with results anticipated in 2028/2029. Moreover, the company is set to release the preliminary findings of a small Phase 1 maintenance trial involving 180 adults to assess optimal dosing regimens.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
